In more detail, considering the drug response behavior of all tested drugs, we found that ibrutinib (BTK/ITK inhibitor targeting B-cell receptor signaling) and ruxolitinib (JAK inhibitor targeting the JAK-STAT pathway) were not suited to strongly reduce the cell viability of T-PLL cancer cells with respect to the underlying dosage schemes. This evidence concerns the gene SOAT1 and cancer.